• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Antimicrobial agents and chemotherapy. >Surveillance of Omadacycline Activity against Clinical Isolates from a Global Collection (North America, Europe, Latin America, Asia-Western Pacific), 2010-2011
【24h】

Surveillance of Omadacycline Activity against Clinical Isolates from a Global Collection (North America, Europe, Latin America, Asia-Western Pacific), 2010-2011

机译：从全球收集（北美，欧洲，拉丁美洲，亚洲西部太平洋），2010-2011的临床孤立禁止临床孤立植物的监测

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Omadacycline is a broad-spectrum aminomethylcycline in late-stage clinical development for the treatment of acute bacterial skin and skin structure infections and community-acquired pneumonia as an oral and an intravenous once-daily formulation. In this study, omadacycline and comparators were tested against 69,246 nonduplicate bacterial isolates collected prospectively during 2010 and 2011 from medical centers in Asia-Pacific (11,397 isolates), Europe (23,490 isolates), Latin America (8,038 isolates), and North America (26,321 isolates). Omadacycline was tested by broth microdilution following Clinical and Laboratory Standards Institute M07-A10 (2015) methods. A total of 99.9% of Staphylococcus aureus isolates were inhibited by <= 2 mu g/ml of omadacycline (MIC50/90, 0.12/0.25 mu g/ml), including 100.0% of methicillin-susceptible S. aureus isolates and 99.8% of methicillin-resistant S. aureus isolates. Omadacycline potencies were comparable for Streptococcus pneumoniae (MIC50/90, 0.06/0.06 mu g/ml), viridans group streptococci (MIC50/90, 0.06/0.12 mu g/ml), and beta-hemolytic streptococci (MIC50/90, 0.06/0.12 mu g/ml) regardless of species and susceptibility to penicillin. Omadacycline was active against Enterobacteriaceae and was most active against Escherichia coli (MIC50/90, 0.5/2 mu g/ml), Enterobacter aerogenes (MIC50/90, 2/4 mu g/ml), Klebsiella oxytoca (MIC50/90, 1/4 mu g/ml), and Citrobacter spp. (MIC50/90, 1/4 mu g/ml). Omadacycline was active against Haemophilus influenzae (MIC50/90, 1/1 mu g/ml) regardless of beta-lactamase status and against Moraxella catarrhalis (MIC5(0/90), 0.12/0.25 mu g/ml). The potent activity of omadacycline against Gram-positive and Gram-negative bacteria indicates that omadacycline merits further study in serious infections in which multidrug resistance and mixed Gram-positive and Gram-negative infections may be a concern.
机译：奥马登霉素是一种广谱氨基甲基环素，其在晚期临床开发中，用于治疗急性细菌皮肤和皮肤结构感染和社区获得的肺炎作为口服和静脉内每日制剂。在本研究中，针对2010年和2011年在亚太地区的医疗中心（11,397耳机），拉丁美洲（8,038个孤立）和北美（26,321）和北美（26,321分离株）。在临床和实验室标准研究所M07-A10（2015）方法后，通过肉汤微量化测试奥马丁素。通过<=2μg/ ml奥布林（MIC50 / 90,0.12 /0.25μg/ ml）抑制总共99.9％的金黄色葡萄球菌分离物，其中包括100.0％的甲氧西林易感金黄色葡萄球菌和99.8％耐甲氧西林的金黄色葡萄球菌分离株。 Omaditycline疗效对于肺炎链球菌（MIC50 / 90,0.06 / mm G / ml），viridans组链球菌（MIC50 / 90,0.06 / ml）和β-溶血性链球菌（MIC50 / 90,0.06 / 0.12 mu g / ml），无论物种和对青霉素的易感性如何。 Omaditycline对肠杆菌痤疮有效，对大肠杆菌（MIC50 / 90,0.5 /2μmg/ ml），肠杆菌空气（MIC50 / 90,2 /4μg/ ml），Klebsiella oxytoca（Mic50 / 90,1 /4μg/ ml）和柠檬杆菌SPP。 （MIC50 / 90,1 /4μg/ ml）。无论β-内酰胺酶状态和对抗MIC5（0/90），0.12 /0.25μg/ ml），omaDaccline都是活性的嗜血杆菌（MIC50 / 90,1 mu g / ml）。奥马基素对革兰氏阳性和革兰氏阴性细菌的有效活性表明omaDitycline在严重感染中进一步研究，其中多药抗性和混合革兰氏阳性和革兰氏阴性感染可能是一个问题。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号